April 20, 2024

• 

[THE INVESTOR] South Korean biopharmaceutical company Medytox announced on Nov. 24 that its hyaluronic filler Neuramis has been approved by the Russian Ministry of Healthcare for sale in the country. 

In addition to the original Neuramis Deep, four different versions of the injectable with local anesthesia lidocaine have been cleared for sales.
Introduced in 2011, the filler lasts longer thanks to a unique stabilized hyaluronic acid and purified enhancement technology, according to Medytox, and has become one of its three major products alongside its flagship botulinum toxins. 

“Russia is one of the largest market for fillers for cosmetic procedures in Europe and along with China, is growing fast,” according to a company official. 

By Hwang You-mee (glamazon@heraldcorp.com)